Welcome to edition seven of The Beghou Biopharma Review by Marc Iskowitz. With the end of the year fast approaching, we wanted to get this edition in your hands before everyone begins to unplug.
First, a heads-up for readers: A Beghou contingent will be on the ground in San Francisco next month for the 44th Annual J.P. Morgan Healthcare Conference, slated for Jan. 12-15, 2026. (If you’d like to connect, email natalie.piepsny@beghou.com to set up a meeting with one of our consultants).
Was 2025 the year of AI agents in life sciences? According to a recent report from Globant and MIT Technology Review Insights, three-quarters of global pharma organizations are currently piloting or deploying agentic AI in their commercial operations.
As agentic AI and generative AI increasingly go mainstream in pharma, the conversation is shifting from what these tools can do to how teams will actually use them and what kinds of intelligence will matter most for commercial and clinical impact.
Let's start with two recent thought pieces from Beghou leaders, who tackle that evolution from different angles.
From chatbots to agents: How GPT-5 is reframing the work
In her piece for HIT Consultant, Beghou Partner Nicole Ventrone charts the industry’s shift from static chatbots to fully autonomous agents — a transition she says marks a new phase in how AI supports clinical and commercial teams. Chatbots, she writes, were never designed for critical thinking. They retrieve information but don’t reason. GPT-5 changes that equation by enabling agents that can process context, take sequential actions, and move workflows forward without constant human prompting.
Ventrone explores how these systems are already being applied across healthcare and pharma, from navigating field inquiries to accelerating trial operations. The throughline is clear: As models become more capable, the real opportunity lies not just in faster answers but in automated execution — work that happens reliably in the background so teams can focus on higher-order decisions.
AI innovation in a budget-constrained year
Despite tighter budgets, AI investment in life sciences is evolving rather than retreating. In Healthcare Business Today, Beghou VP of AI Innovation Pradeepta Mishra makes the case that companies are becoming more selective and more grounded, prioritizing use cases that deliver measurable impact rather than experimenting broadly.
He highlights three areas where AI is proving resilient: driving operational efficiency, enhancing productivity for scientific and commercial teams, and improving decision-making with better-integrated data. The common thread is a shift toward targeted innovation — deploying AI where it can shorten cycles, reduce friction, or improve forecasting without demanding sweeping organizational change. It’s a pragmatic roadmap for advancing AI even when resources are constrained. Read the full article here.
Beghou deep cut: Finding your organizational harmony
Some parts of an organization can be strong on their own and still feel out of sync together. Over more than 30 years of consulting in life sciences, we’ve seen that lack of cohesion manifest in different shapes: misaligned teams, fragmented tech stacks, and data signals no one is fully equipped to act on. But the effect is the same. When the rhythm is off, commercial performance follows.
As part of our Commercialization That Works research, we introduced four musical archetypes: soundcheck mode, garage band, chamber orchestra, and smooth jazz ensemble. This matrix (pictured above) is designed to help organizations pinpoint where they sit in terms of cohesiveness. With the right balance of structure and agility, organizations can get all facets of their commercialization apparatus swinging like a smooth jazz ensemble, which is the ultimate goal.
If you want to dig deeper into how teams can move toward the version of harmony that adapts under pressure, here are the webinar video and slides from “Rethinking Life Sciences Commercialization for 2026: What’s Working, What’s Not, and What’s Next.” We’ll be publishing the full report from our research early next year.
That’s it for now. If you’re looking for more context on any of these stories, drop me a line at marc.iskowitz@beghou.com
Cheers,
Marc Iskowitz
Editorial Director, Beghou
P.S. Thank you for reading and to my Beghou colleague Sravya Narayanaswamy for helping me put this together.